[News] Study bolsters concerns about US FDA accelerated drug approvals

April, 04, 2024 | Select Oncology Journal Articles

Half of the cancer drugs granted expedited approval by the US Food and Drug Administration (FDA) between 2013 and 2017 failed to show clinical benefits for patients in confirmatory trials more than 5 years later, according to a study by Liu and colleagues published in JAMA on April 7, 2024, and presented at the American Association of Cancer Research’s 2024 annual meeting. Of 39 confirmatory trials, 19 showed no overall survival or quality of life benefits for patients. Confirmatory studies had not yet been completed for seven other cancer drugs granted accelerated approval.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy